{"description":"Documents matching 'Pharmacy Compounding Advisory Committee' and published on or after 07/24/2026","count":7,"total_pages":1,"results":[{"title":"Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Cardiovascular and Renal Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cardiovascular and Renal Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2028, expiration date.","document_number":"2026-16999","html_url":"https://www.federalregister.gov/documents/2026/08/20/2026-16999/advisory-committee-cardiovascular-and-renal-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16999.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16999.pdf?1787143523","publication_date":"2026-08-20","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Metabolic Drugs Advisory Committee \n • Genetic Metabolic Disease Advisory Committee \n • Medical Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Psychopharmacologic Drugs Advisory Committee \n • Pulmonary-Allergy"},{"title":"Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the renewal of the Endocrinologic and Metabolic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Endocrinologic and Metabolic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2028, expiration date.","document_number":"2026-16998","html_url":"https://www.federalregister.gov/documents/2026/08/20/2026-16998/advisory-committee-endocrinologic-and-metabolic-drugs-advisory-committee-renewal","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-20/pdf/2026-16998.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16998.pdf?1787143523","publication_date":"2026-08-20","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Metabolic Drugs Advisory Committee \n • Genetic Metabolic Disease Advisory Committee \n • Medical Devices Advisory Committee \n • National Mammography Quality Assurance Advisory Committee (Administratively Inactive) \n • Nonprescription Drugs Advisory Committee \n • Obstetrics, Reproductive and Urologic Drugs Advisory Committee \n • Oncologic Drugs Advisory Committee \n • Pediatric Advisory Committee \n • Peripheral and Central Nervous System Advisory Committee \n • Pharmacy Compounding Advisory Committee \n • Psychopharmacologic Drugs Advisory Committee \n • Pulmonary-Allergy"},{"title":"Notice Regarding 340B Rebate Model Pilot Program","type":"Notice","abstract":"The U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA), which administers the 340B Drug Pricing Program (340B Program), is issuing this Notice to announce the availability of a revised 340B Rebate Model Pilot Program (Pilot). The Pilot provides a rebate mechanism through which qualifying drug manufacturers may effectuate the 340B ceiling price for certain drugs sold to covered entities. Consistent with HRSA's longstanding statutory authority, rebates will be used instead of upfront discounts. HRSA issued a Request for Information (RFI) \\1\\ to gather input from interested parties regarding the potential use of rebates to effectuate the ceiling price under the 340B Program, including the standards and procedures that should govern the approval of manufacturer rebate plans and the impacts on all stakeholders. After carefully considering all comments from interested parties and different policy alternatives, HRSA is announcing this Pilot, which will implement a rebate approach for a limited set of drugs, and which builds on established and successful rebate programs. ---------------------------------------------------------------------------","document_number":"2026-15633","html_url":"https://www.federalregister.gov/documents/2026/08/03/2026-15633/notice-regarding-340b-rebate-model-pilot-program","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-03/pdf/2026-15633.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-15633.pdf?1785501912","publication_date":"2026-08-03","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Health Resources and Services Administration","name":"Health Resources and Services Administration","id":222,"url":"https://www.federalregister.gov/agencies/health-resources-and-services-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/222","parent_id":221,"slug":"health-resources-and-services-administration"}],"excerpts":"arrangements with contract pharmacies. \n A 340B contract pharmacy is a retail or specialty pharmacy that has entered into a formal agreement with a covered entity to dispense drugs on the covered entity's behalf. Because many covered entities, such as federally qualified health centers, lack the ability to operate their own in-house pharmacy, contract pharmacy arrangements provide a mechanism to extend their 340B Program benefits to eligible patients by leveraging existing pharmacy infrastructure. Under this arrangement, a contract pharmacy dispenses drugs"},{"title":"Medicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements","type":"Rule","abstract":"This final rule updates the hospice wage index, payment rates, and aggregate cap amount for fiscal year 2027. This final rule also includes an analysis of Medicare non-hospice spending, including details regarding a hospice service and spending variation index, and finalizes the requirement that hospices provide the hospice election statement addendum to all Medicare beneficiaries at the time of hospice election. Additionally, this rule finalizes conforming changes to discharge from hospice care regulations and changes to the face-to-face encounter regulations. This final rule also includes a summary of comments received on our requests for information regarding community- based palliative care; the construction of a hospice specific wage index; and the overlap between hospice and medical aid in dying laws. Finally, this rule finalizes changes to the Hospice Quality Reporting Program.","document_number":"2026-15686","html_url":"https://www.federalregister.gov/documents/2026/08/03/2026-15686/medicare-program-fy-2027-hospice-wage-index-and-payment-rate-update-and-hospice-quality-reporting","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-03/pdf/2026-15686.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-15686.pdf?1785442510","publication_date":"2026-08-03","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"407) = $41,284,240.23.\n \n For pharmacies dispensing Part D drugs to hospice beneficiaries, the estimated burden for the pharmacy technician at the point of service to contact the hospice to obtain the needed clinical information regarding the drugs deemed by the hospice as unrelated to the terminal illness and related conditions would be 15 minutes (15/60 = 0.25). The average number of hospice beneficiaries receiving services per pharmacy dispensing Part D maintenance drugs is 18.6 per year, which would mean each pharmacy would have an average of 18"},{"title":"Reducing Barriers to Medical Use Licensing","type":"Proposed Rule","abstract":"The U.S. Nuclear Regulatory Commission (NRC) is proposing to amend its regulations to reduce barriers to medical use licensing. This proposed rule responds to Executive Order 14300, \"Ordering the Reform of the Nuclear Regulatory Commission,\" which requires the NRC to conduct a review and wholesale revision of its regulations. This proposed rule, if adopted, would reduce overly prescriptive regulations, increase flexibility, and modernize radiation safety practices for the medical use of byproduct material. It also would enable more efficient and predictable licensing for emerging medical technologies and reduce unnecessary burden in training and experience requirements for medical authorized users. The NRC is revising guidance for this proposed rule. This proposed rule also would incorporate minor editorial corrections.","document_number":"2026-15080","html_url":"https://www.federalregister.gov/documents/2026/07/27/2026-15080/reducing-barriers-to-medical-use-licensing","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-27/pdf/2026-15080.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-15080.pdf?1784897111","publication_date":"2026-07-27","agencies":[{"raw_name":"NUCLEAR REGULATORY COMMISSION","name":"Nuclear Regulatory Commission","id":383,"url":"https://www.federalregister.gov/agencies/nuclear-regulatory-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/383","parent_id":null,"slug":"nuclear-regulatory-commission"}],"excerpts":"require all candidates for certification to: \n \n (1) Have graduated from a pharmacy program accredited by the Accreditation \n \n Council for Pharmacy Education (ACPE) (previously named the American Council on Pharmaceutical Education) or have passed the Foreign Pharmacy Graduate Examination Committee (FPGEC) examination;\n \n (2) Hold a current, active license to practice pharmacy; \n (3) Provide evidence of having acquired at least 4000 hours of training/experience in nuclear pharmacy practice. Academic training may be substituted for no more than 2000 hours"},{"title":"Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children","type":"Rule","abstract":"This final rule requires that a State Medicaid plan must provide that the Medicaid agency will not make payment under the plan for sex-rejecting procedures for children under 18, and prohibits the use of Federal Medicaid dollars to fund sex-rejecting procedures for individuals under the age of 18. In addition, this final rule requires that a separate State Children's Health Insurance Program (CHIP) plan must provide that the CHIP agency will not make payment under the plan for sex-rejecting procedures for children under 19, and prohibits the use of Federal CHIP dollars to fund sex-rejecting procedures for individuals under the age of 19. For Medicaid and CHIP beneficiaries who are actively receiving cross-sex hormone therapy, State Medicaid and CHIP agencies may continue to claim Federal Financial Participation for those hormone therapy medications for a period of up to 6 months from the effective date of this final rule.","document_number":"2026-16508","html_url":"https://www.federalregister.gov/documents/2026/08/13/2026-16508/medicaid-program-prohibition-on-federal-medicaid-and-childrens-health-insurance-program-funding-for","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-13/pdf/2026-16508.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16508.pdf?1786479307","publication_date":"2026-08-13","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"that it was conducting its own review of the evidence and developing expanded guidance—which still have not been released as of July 2026.\n 79 \n \n Regarding the AAP policy statement, the HHS Review states:\n \n \n \n 78 \n Jason Rafferty, AAP Committee on Psychosocial Aspects of Child and Family Health, AAP Committee on Adolescence, AAP Section on Lesbian, Gay, Bisexual, and Transgender Health and Wellness, “Ensuring Comprehensive Care and Support for Transgender and Gender Diverse Children and Adolescents,” \n Pediatrics \n 142, no. 4 (2018), \n doi.org/10"},{"title":"Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; Other Policy Changes; and Adoption of Updated Versions of Certain Health Information Technology Standards","type":"Rule","abstract":"This final rule will revise the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals; make changes relating to Medicare graduate medical education (GME) for teaching hospitals; update the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs); update and make changes to requirements for certain quality programs; and make other policy- related changes. ONC also adopts certain health information technology (health IT) standards and specifications on behalf of HHS.","document_number":"2026-15833","html_url":"https://www.federalregister.gov/documents/2026/08/04/2026-15833/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-ipps-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-04/pdf/2026-15833.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-15833.pdf?1785528912","publication_date":"2026-08-04","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"},{"raw_name":"Office of the Secretary"}],"excerpts":"Federal Advisory Committee Activities \n The HITECH Act established two federal advisory committees, the Health IT Policy Committee (hereinafter referred to as the “HITPC”) and the Health IT Standards Committee (hereinafter referred to as the “HITSC”). Each committee was responsible for advising the National Coordinator on different aspects of health IT policy, standards, implementation specifications, and certification criteria. \n Section 4003(e) of the Cures Act amended section 3002 of the PHSA and replaced the HITPC and HITSC with one committee, the"}]}